DELANEY MARK E sold $376K of DGX
DELANEY MARK E (SVP & Chief Commercial Officer) sold 1,600 shares of QUEST DIAGNOSTICS INC (DGX) at $235.18 ($0.38M total) on 2026-07-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is open-market and pre-arranged under a 10b5-1 plan, it is generally not a strong standalone catalyst for trading decisions.
Market read
Traders may note the filing for completeness, but it does not introduce new fundamental information.
What to watch
The transaction size and the fact it is a planned 10b5-1 sale make it less informative than unscheduled sales or purchases tied to specific events.
Background
The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).
Ticker impact
Quest Diagnostics Form 4 shows SVP Mark E Delaney sold 1,600 shares on 2026-07-28 under a pre-arranged 10b5-1 plan.
Likely minimal impact on DGX price; any effect is typically short-lived and outweighed by broader fundamentals.
The filing is a Form 4 insider transaction, explicitly pre-arranged under Rule 10b5-1, and provides no new company-specific operational or financial information.
Market effects
No direct read-across to diagnostics sector fundamentals from a single routine insider sale.
None.
None.
Counterpoint
Insider sales can sometimes reflect private risk perceptions, but the 10b5-1 pre-arrangement reduces interpretability.
Key entities
- issuerQuest Diagnostics
DGX, the company whose insider transaction is disclosed.
- insiderDelaney Mark E
SVP and Chief Commercial Officer who sold shares.
- trading_ruleRule 10b5-1 plan
Pre-arranged plan that typically limits the informational value of the sale.
